EWTX (Edgewise Therapeutics) Total Operating Expense: $199.56 Mil (TTM As of Mar. 2026)


EWTX Edgewise Therapeutics Inc EWTX
28 GF Score
Price $41.95
! 3 Warning Signs
View Full Analysis

What is Edgewise Therapeutics Total Operating Expense?

Edgewise Therapeutics EWTX +7.95% 28 Total Operating Expense is $199.56 Mil as of Mar. 2026. GuruFocus rates EWTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Edgewise Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $54.12 Mil. Edgewise Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $199.56 Mil.

Edgewise Therapeutics Total Operating Expense Related Terms

Edgewise Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Edgewise Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edgewise Therapeutics Total Operating Expense Chart

Edgewise Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 43.22 71.66 114.36 158.83 191.41

Edgewise Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.96 42.61 46.86 55.98 54.12
EWTX
28GF Score
Edgewise Therapeutics Inc EWTX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edgewise Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $199.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $199.56 Mil mean?
Edgewise Therapeutics (EWTX) has a Total Operating Expense of $199.56 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Edgewise Therapeutics and its competitors.
Is Edgewise Therapeutics' Total Operating Expense too high?
Edgewise Therapeutics' current Total Operating Expense is $199.56 Mil. Overall, Edgewise Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Edgewise Therapeutics' Total Operating Expense compare to ACAD and CRNX?
Edgewise Therapeutics' Total Operating Expense of $199.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Edgewise Therapeutics and its competitors. Edgewise Therapeutics's current Total Operating Expense is $199.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edgewise Therapeutics stock overvalued right now?
Edgewise Therapeutics (EWTX) has a current Total Operating Expense of $199.56 Mil. The current Total Operating Expense is $199.56 Mil. Edgewise Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Edgewise Therapeutics (EWTX), the current Total Operating Expense is $199.56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edgewise Therapeutics Business Description

Address 1715 38th Street, Boulder, CO, USA, 80301
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
28GF Score

Get the complete analysis for EWTX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.95
Price